MedWatch Technologies

What MedWatch Technologies does

MedWatch Technologies, Inc. is a Delaware-incorporated medical device and software company founded in 2022 that is developing a non-invasive health management platform for metabolic health. The company's product portfolio centers on a wearable, microwave-based glucose biosensor designed to monitor glucose levels continuously without needles or blood samples, paired with an AI-powered lifestyle coaching platform intended to deliver personalized metabolic wellness recommendations. Co-developed with the Alberta Diabetes Institute, the biosensor technology is backed by a co-developed provisional patent and has progressed to in-human testing. The company has also acquired Sensable Health, a metabolic wellness app, which is being integrated into the broader platform vision.

The technology stack combines proprietary microwave-sensor hardware (developed by CTO Masoud Baghelani during his University of Alberta postdoctoral fellowship) with a software coaching layer built on neurosymbolic AI, reinforcement learning, and agentic orchestration led by CTO Bruce Matichuk. Target customer segments include individuals with Type 1, Type 2, or pre-diabetes who need continuous glucose monitoring without invasive finger pricks, as well as health-conscious consumers seeking proactive metabolic health management. The company is pre-commercialization, pre-revenue, and has not yet obtained FDA clearance for its biosensor.

MedWatch Technologies' business model is planned as subscription/recurring revenue tied to the biosensor and coaching platform, but no pricing has been publicly disclosed and no products are currently sold. To date, the company has raised approximately $32.5 million in aggregate through a $15 million Series A led by Stead Impact Ventures in January 2026 and a Rule 506(b) SEC exempt offering that has sold $17.55 million to 118 investors against a $29.48 million target. As part of the Series A, MedWatch acquired Sensable Health from Stead Impact Ventures and added Stead's CCO Aidan Thompson to its board. Current operations are primarily R&D and investor-relations driven, with go-to-market still dependent on FDA clearance.

Name

MedWatch Technologies

Legal name

MedWatch Technologies, Inc.

Website

https://medwatchtech.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

MedWatch Technologies is developing a non-invasive microwave-based glucose biosensor paired with an AI-driven metabolic health coaching platform. The pre-revenue, pre-FDA-clearance company targets individuals with diabetes and pre-diabetes as well as health-conscious consumers seeking proactive metabolic wellness management.

Ownership category

akta.pro rank

Product category

Continuous Glucose Monitoring Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Continuous Glucose Monitoring (CGM) Systems (HLAHAHAA)

akta.pro secondary industries

Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators) (HLAHAHAJ), Biosensors & Lab-on-Chip (BioMEMS) (HDAHALAK), Blood Glucose Monitoring Devices (Consumer CGM & Smart Glucometers) (CRACAQAE)

Keywords

• Non-invasive glucose monitoring
• Continuous glucose monitoring
• Metabolic health management
• AI health coaching
• Wearable biosensor technology

Headquarters

HQ city

Las Vegas

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Pre-Revenue Stage: The company is in pre-revenue stage with product in development and no FDA clearance obtained. The company declined to disclose revenue information in SEC filings. Revenue generation will commence upon successful development and commercialization of the non-invasive glucose monitoring platform.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

MedWatch Technologies is developing a non-invasive metabolic health management platform that pairs a wearable microwave-based glucose biosensor (built in collaboration with the Alberta Diabetes Institute) with an AI-powered lifestyle coaching platform that delivers personalized metabolic health recommendations. The biosensor monitors glucose continuously without needle-based blood sampling, and the coaching layer uses neurosymbolic AI and reinforcement learning for proactive health management. All offerings are pre-commercialization; the product is in development and has not received FDA clearance.

Product overview

MedWatch Technologies is developing a non-invasive health management platform consisting of three integrated components: a non-invasive glucose biosensor wearable device, an integrated AI-powered lifestyle coaching platform, and the Sensable Health metabolic wellness app (acquired). The biosensor uses microwave sensor technology to monitor glucose without blood draws, while the coaching platform leverages AI to deliver personalized metabolic wellness recommendations. All products are in development and have not received FDA clearance.

Differentiator

Problem solved

Functional benefit

Products and services

• Non-Invasive Glucose Biosensor Wearable, non-invasive biosensor device that monitors glucose continuously without needles or blood samples, using proprietary microwave sensor technology co-developed with the Alberta Diabetes Institute. Targeted at individuals with diabetes, pre-diabetes, and health-conscious consumers seeking proactive metabolic monitoring.
• Integrated Lifestyle Coaching Platform AI-powered coaching platform that delivers proactive metabolic health management recommendations based on data from the non-invasive biosensor, using neurosymbolic AI, reinforcement learning, and agentic orchestration. Intended for the same diabetes, pre-diabetes, and wellness consumer audience as the biosensor.
• Sensable Health Metabolic Wellness App Metabolic wellness mobile application acquired from Sensable Health whose coaching flows align with MedWatch's platform vision, supporting lifestyle coaching integration within the broader MedWatch offering.

Quantifiable outcome

• Non-invasive glucose monitoring eliminates needle-based blood sampling
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature3 records

Partnerships

One partnership is on record.

• Sensable HealthcoreStrategic or Co-development Partner · 14 January 2026MedWatch Technologies completed the acquisition of Sensable Health, a portfolio company of Stead Impact Ventures. Sensable Health's metabolic wellness app aligns with MedWatch's platform vision and will be integrated into the company's comprehensive health management platform. This acquisition supports platform integration and expands MedWatch's capabilities in metabolic wellness coaching.

Scale indicators5 records

Recent moves5 records

Expansion highlights6 records

Broad incumbents

• Dexcom: Dexcom is the leading U.S. continuous glucose monitoring company with G6/G7 sensors and a dominant prescriber- and payor-covered franchise. It is the most relevant incumbent competitor; MedWatch's non-invasive value proposition is positioned directly against Dexcom's invasive CGM category leadership.
• Medtronic: Medtronic's Guardian and forthcoming CGM products, paired with its diabetes insulin-pump business, form an integrated automated insulin delivery ecosystem. Relevant as a broad incumbent in the diabetes monitoring and delivery category.
• mySugr (Roche): mySugr, owned by Roche, is a leading diabetes self-management app integrated with Roche's Accu-Chek and broader diabetes ecosystem. Relevant comparable for MedWatch's planned consumer coaching software layer adjacent to glucose data.
• Abbott (FreeStyle Libre): Abbott's FreeStyle Libre is the highest-volume consumer-accessible CGM globally, including over-the-counter Libre Rio/Libre 3 Plus in some markets. Comparable because it dominates the consumer-friendly end of the glucose monitoring category that MedWatch is targeting.

Direct peers

• January AI: January AI focuses on predictive metabolic health using multi-sensor data and AI-driven recommendations. Relevant emerging player in the AI-powered metabolic wellness space that MedWatch targets, with a comparable consumer coaching + data subscription model.
• Levels Health: Levels sells a consumer subscription that pairs CGM data with software-driven metabolic coaching. Highly comparable to MedWatch's planned biosensor-plus-AI-coaching platform, although Levels currently relies on third-party CGMs rather than proprietary sensors.
• Senseonics (Eversense): Senseonics produces the Eversense implantable CGM, the longest-duration CGM on market. Comparable as a glucose-monitoring company pursuing an alternative form factor (implantable vs MedWatch's non-invasive), with the same FDA-driven regulatory pathway and payor-reimbursement dependencies.
• Know Labs: Know Labs is developing a non-invasive glucose monitor using RF/bio-RFID spectroscopy, with a similar scientific premise to MedWatch's microwave-sensor approach. Direct competitor in the non-invasive glucose monitoring race and a useful valuation/development-stage comparable.

Emerging players

• Virta Health: Virta Health is a digital health company providing AI-assisted, clinician-supervised diabetes reversal and metabolic health programs. Comparable as a coaching-and-data-driven diabetes/metabolic health business targeting similar patient and consumer segments.
• Omada Health: Omada Health combines connected devices, behavioral coaching, and AI-driven personalization for chronic conditions including diabetes and pre-diabetes. Comparable as an AI-enabled metabolic health coaching platform with payor and employer channels.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks3 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/medwatchtechnologies

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries1 record

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MedWatch Technologies